223514-71-4

Usage

Uses

Used in Pharmaceutical Industry:
(R)-N-(1-(4-chloromethylphenyl)ethyl)acetamide is used as a potential active pharmaceutical ingredient for the development of new drugs. Its unique structure, including the 4-chloromethylphenyl group, may allow it to interact with biological targets in ways that could be beneficial for treating specific medical conditions.
Used in Agrochemical Industry:
In the agrochemical sector, (R)-N-(1-(4-chloromethylphenyl)ethyl)acetamide may be utilized as a component in the development of novel pesticides or herbicides. Its chemical properties could potentially be harnessed to target and control pests or weeds more effectively and selectively.
Used in Chemical Research:
(R)-N-(1-(4-chloromethylphenyl)ethyl)acetamide serves as a valuable compound for research purposes in the field of organic chemistry. Its chiral center and unique structural features make it an interesting subject for studying reaction mechanisms, stereochemistry, and the development of new synthetic methods.
Used in Material Science:
(R)-N-(1-(4-chloromethylphenyl)ethyl)acetamide may also find applications in material science, where its specific properties could be exploited to create new materials with tailored characteristics for various industrial applications, such as in coatings, adhesives, or polymers.

Upstream product

• 859163-61-4 (R)-4-(1-acetamidoethyl)benzoic acid 
• 173898-18-5 (R)-N-(4-methoxycarbonylphenylethyl)acetamide 
• 88146-37-6 (R)-N-(1-(4-acetylphenyl)ethyl)acetamide 
• 36283-44-0 N-acetyl-1-phenylethylamine 
• 3886-69-9 (R)-1-phenyl-ethyl-amine 
• 223514-69-0 (R)-N-(1-(4-hydroxymethylphenyl)ethyl)acetamide 

Relevant academic research and scientific papers

Piperazine compounds and medicinal use thereof

The present invention relates to a piperazine compound of the formula wherein R1and R2are each hydrogen, halogen, lower alkyl, lower alkoxy, amino, substituted amino, nitro, hydroxy or cyano, R3, R4and R5are each hydrogen, halogen, lower alkyl, lower alkoxy, nitro, amino, substituted amino or hydroxy, R6and R7are each hydrogen, lower alkyl, lower alkyl substituted by halogen, aralkyl, acyl or lower acyl substituted by halogen, R8and R9are each hydrogen or lower alkyl, Y is lower alkylene and the like, and ring A is phenyl, pyrimidyl, thiazolyl, pyridyl, pyrazyl or imidazolyl, a pharmaceutically acceptable salt thereof and pharmaceutical agents containing these compounds. The compound of the present invention has superior TNF-α production inhibitory effect and/or IL-10 production promoting effect, and, since it is free of or shows only strikingly reduced expression of an effect on the central nervous system, the compound is useful as a highly safe and superior TNF-α production inhibitor an/or IL-10 production promoter and is useful as an agent for the prophylaxis or treatment of various diseases caused by abnormal TNF-α production, diseases curable with IL-10, such as chronic inflammatory diseases, acute inflammatory diseases, inflammatory diseases due to infection, autoimmune diseases, allergic diseases, and TNF-α mediated diseases.

Novel DMARDs on the basis of a new concept of dual cytokine regulation, TNF-α suppression and IL-10 augmentation

A series of arylpiperazine derivatives was synthesized to obtain agents showing apparent therapeutic effects in a chronic inflammatory animal model, starting from a lead possessing potent dual cytokine regulatory activity in vivo. We found a pyrimidylpipe